/
FDMT
$11.65-$0.22 (-1.85%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$620.5M
52M shares
52-week range
$5.97 – $14.00
71% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-16.25
4D Molecular Therapeutics, Inc. Common Stock
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
www.4dmoleculartherapeutics.com- Employees
- 196
- IPO / List date
- Dec 11, 2020
- HQ
- EMERYVILLE, CA
Held by traders on TradeandTell
No one on the platform currently holds FDMT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 578,265 | $5.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FDMT yet.
